Investigación: Semaglutide

GLP-1 receptor agonist for weight loss and diabetes management

Wilding et al. 2021 — STEP 1: Semaglutide for Obesity

NEJM 2021 3200 Clinical Trial

Once-weekly semaglutide 2.4mg achieved 14.9% weight loss over 68 weeks vs 2.4% placebo in adults with obesity; 69.1% achieved >=10% weight loss.